Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Primary Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)

Slavisa Ninkovic, Costas K. Yannakou, Nicholas Murphy, Rosemary Anne Harrup, Craig Wallington-Gates, Magdalena Sobieraj-Teague, M Hasib Sidiqi, Anish Puliyayil, Wojt Janowski, John Reynolds, Andrew Spencer, Hang Quach

Blood (2023) 142 (Supplement 1): 2019.

https://doi.org/10.1182/blood-2023-185944

Published: 2023

Journal Articles

A Phase I/II Single Arm Study of Belantamab Mafodotin, Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Planned Interim Analysis of Safety and Efficacy. Amarc 19-02 Belacard Study

Masa Lasica, Andrew Spencer, Noemi Horvath, Wojt Janowski, Douglas Coghlan, Craig Wallington-Gates, Philip Campbell, Hock Choong Lai, Georgia McCaughan, Nicholas Weber, Anish Puliyayil, Philip Wong, Deng Yachao, Khoa Le, John Reynolds, Hang Quach

Blood (2023) 142 (Supplement 1): 2012.

https://doi.org/10.1182/blood-2023-189005

Published: 2023

Journal Articles

Secondary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Sueh-li Lim, John Reynolds, Hang Quach, Anna Hutchinson, Ian H Kerridge, Jane Estell, Craig wallington-Gates, Anna Kalff, Flora Yuen, Andrew Spencer

Blood (2022) 140 (Supplement 1): 10174–10176.

https://doi.org/10.1182/blood-2022-170697

Published: 2022